Clinical value of IL-17-targeted intervention in tissue injury repair: from bidirectional mechanisms to therapeutic strategies - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Therapeutic Potential of Targeting IL-17 in Tissue Repair: Exploring Dual Mechanisms and Treatment Approaches

  • By

  • Wenyu An

  • Xinyi Ma

  • Runxue Guan

  • Yufen Zhao

  • Nina Yang

  • Liang Jin

  • Yang Jian

  • Shaoying Gao

  • Zairong Wei

  • June 2, 2026

Share

Clinical Scorecard: The Therapeutic Potential of Targeting IL-17 in Tissue Repair: Exploring Dual Mechanisms and Treatment Approaches

At a Glance

CategoryDetail
Condition
Key MechanismsIL-17 signaling through IL-17R activates pathways like NF-κB, MAPK, JAK/STAT, influencing inflammation and tissue regeneration; specify effects on each pathway.
Target Population
Care Setting

Key Highlights

  • additional_highlight

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • I
      • n
      • c
      • l
      • u
      • d
      • e
      • s
      • p
      • e
      • c
      • i
      • f
      • i
      • c
      • i
      • n
      • f
      • l
      • a
      • m
      • m
      • a
      • t
      • o
      • r
      • y
      • m
      • a
      • r
      • k
      • e
      • r
      • s
      • s
      • u
      • c
      • h
      • a
      • s
      • C
      • R
      • P
      • a
      • n
      • d
      • I
      • L
      • -
      • 6
      • t
      • o
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • .

      Risks

        Patient & Prescribing Data

        Individuals with acute and chronic tissue injuries.

        IL-17 targeting may enhance tissue repair while managing inflammation.

        Clinical Best Practices

        • evidence

        Related Resources & Content

        Original Source(s)

        Clinical value of IL-17-targeted intervention in tissue injury repair: from bidirectional mechanisms to therapeutic strategies

        • by Wenyu An, Xinyi Ma, Runxue Guan, Yufen Zhao, Nina Yang, Liang Jin, Yang Jian, Shaoying Gao, Zairong Wei

        • June 2, 2026

        Related Content

        Expanding the donor pool in secondary AML: a step forward, with caveats

        DOJ Announces First Health Care Company Declination

        Campus Eye avoided prosecution after voluntarily disclosing misconduct, cooperating with investigators, and remediating the wrongdoing.

        Phoenix Children’s Joins First Controlled Clinical Trial of Genetic Therapy for Dravet Syndrome

        The first controlled phase 3 trial of a genetic therapy for Dravet syndrome is now underway – with Phoenix Children's as one of 28 sites nationwide.

        • by

        • August 13, 2026

        • 4 min